Lundbeck advances Parkinson's research with new Phase 1b data at AD/ PD™ 2026

H. Lundbeck A/S Denmark

Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson's disease, to be presented at the 2026 AD/PD™ ConferenceData evaluated safety, tolerability, pharmacokinetics and early clinical signals of Lu AF28996Five accepted presentations reflect Lundbeck's growing pipeline within movement disorders, with Parkinson's disease and multiple system atrophy (MSA) clinical development programsand connect with us via LinkedIn.

References:

Heim B and Poewe W. J Parkinsons Dis 2025;23Cenci MA. Front Neurol 2014;5:242Stocchi F et al. Nat Rev Neurol 2024;20:695–707Jellinger KA. J Alzheimers Dis. 2018;62:1141–79

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/h--lundbeck-a-s/r/lundbeck-advances-parkinson-s-research-with-new-phase-1b-data-at-ad-pd--2026,c4321234

The following files are available for download:

https://mb.cision.com/Main/18215/4321234/3982505.pdf

ADPD Curtain Raiser _Final

 

View original content:https://www.prnewswire.co.uk/news-releases/lundbeck-advances-parkinsons-research-with-new-phase-1b-data-at-adpd-2026-302714458.html